VersaBank (VBNK)
(Delayed Data from NSDQ)
$13.70 USD
-0.02 (-0.15%)
Updated Jan 3, 2025 04:00 PM ET
After-Market: $13.73 +0.03 (0.22%) 7:58 PM ET
5-Strong Sell of 5 5
D Value A Growth C Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
VBNK 13.70 -0.02(-0.15%)
Will VBNK be a Portfolio Killer in January?
Zacks Investment Research is releasing its prediction for VBNK based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VBNK
VersaBank (VBNK) Q4 Earnings Surpass Estimates
PennantPark (PNNT) Q4 Earnings Match Estimates
VBNK: What are Zacks experts saying now?
Zacks Private Portfolio Services
StoneX Group Inc. (SNEX) Surpasses Q4 Earnings and Revenue Estimates
Sphere 3D Corp. (ANY) Surpasses Q3 Earnings Estimates
Fidelis Insurance Holdings (FIHL) Q3 Earnings Top Estimates
Other News for VBNK
VersaBank: High ROE, High Growth And Low Risk
VersaBank Secures Additional Capital Through Exercise of Over-Allotment Option
VersaBank Successfully Completes Public Offering of Common Shares
Pfizer provides FY25 outlook, McCormick in talks for Sauer Brands: Morning Buzz
Pfizer provides FY25 outlook, McCormick in talks for Sauer Brands: Morning Buzz